The implications of diagnosing women’s health problems extend far beyond each patient, affecting partners and children as well. Particularly when it comes to infectious disease, it’s essential to get rapid, reliable answers from lab tests.
Luminex’s Women’s Health assays, ranging from antenatal testing to sexually transmitted infections, offer highly sensitive, accurate, and easy to use PCR-based options that enable laboratories to provide physicians and patients with precise results.
Our ARIES® assays can be scaled to meet the throughput needs of labs ranging from community hospitals to large reference facilities. These assays are designed to run on ARIES® Systems, which are sample to answer platforms that require minimal hands-on time, and offer the flexibility to run both IVD assays and laboratory developed tests.
Learn more about our women’s health testing options:
Looking to design your own assay? We offer a diverse portfolio of primers for bacterial, fungal, protozoan, and viral pathogens. Learn more about MultiCode® Analyte Specific Reagents.***
Help Save a Baby by Spreading the Word About GBS — Luminex Blog
*For In Vitro Diagnostic Use. Products are region specific and may not be approved in some countries/regions. Please contact Luminex at email@example.com to obtain the appropriate product information for your country of residence.
**EUA – In Vitro Diagnostic Use Under Emergency Use Authorization. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization for use by authorized laboratories. This test has been authorized only for the detection of RNA from Zika virus and diagnosis of Zika virus infection, not for any other viruses or pathogens. This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of Zika virus and/or diagnosis of Zika virus infection under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
***Analytical and performance characteristics are not established.